Soleno Therapeutics (SLNO) Enterprise Value (2013 - 2026)
Soleno Therapeutics (SLNO) posted quarterly Enterprise Value of -$255.6 million for Q1 2026, up 11.85% year-over-year from -$228.5 million in Q1 2025, and up 16.34% quarter-over-quarter from -$305.5 million in Q4 2025.
Soleno Therapeutics (SLNO) Enterprise Value (2013 - 2026) Analysis & Trends
Soleno Therapeutics (SLNO) has reported Enterprise Value for 14 consecutive years, with -$255.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value rose 11.85% year-over-year to -$255.6 million; the TTM figure through Mar 2026 stood at -$255.6 million (up 11.85% YoY), while the FY2025 annual figure was -$305.5 million, down 4.82% from the prior year.
- Enterprise Value advanced to -$255.6 million in Q1 2026 per SLNO's latest filing, from -$305.5 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$7.9 million in Q1 2023 and bottomed at -$499.0 million in Q3 2025.
- Historically, Enterprise Value has averaged -$172.8 million across 5 years, with a median of -$169.7 million in 2023.
- Annual changes were most pronounced in 2023 — Enterprise Value soared 72.73% — and 2024, when it slumped 1793.67%.
- Soleno Therapeutics' Enterprise Value stood at -$14.6 million in 2022, then tumbled by 1062.04% to -$169.7 million in 2023, then sank by 71.76% to -$291.4 million in 2024, then dropped by 4.82% to -$305.5 million in 2025, then advanced by 16.34% to -$255.6 million in 2026.
- Business Quant data shows SLNO's Enterprise Value at -$255.6 million in Q1 2026, -$305.5 million in Q4 2025, and -$499.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Soleno Therapeutics | 2.74 Bn | 2.49 Bn | 93.41 Mn | -255.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -255.57 Mn |
| Dec 31, 2025 | -305.47 Mn |
| Sep 30, 2025 | -498.97 Mn |
| Jun 30, 2025 | -286.84 Mn |
| Mar 31, 2025 | -289.93 Mn |
| Dec 31, 2024 | -291.44 Mn |
| Sep 30, 2024 | -256.78 Mn |
| Jun 30, 2024 | -266.10 Mn |
| Mar 31, 2024 | -149.60 Mn |
| Dec 31, 2023 | -169.68 Mn |
| Sep 30, 2023 | -52.40 Mn |
| Jun 30, 2023 | -19.40 Mn |
| Mar 31, 2023 | -7.90 Mn |
| Dec 31, 2022 | -14.60 Mn |
| Sep 30, 2022 | -19.75 Mn |
| Jun 30, 2022 | -24.10 Mn |
| Mar 31, 2022 | -28.97 Mn |
| Dec 31, 2021 | -21.30 Mn |
| Sep 30, 2021 | -28.19 Mn |
| Jun 30, 2021 | -33.60 Mn |